Aerobic glycolysis is a metabolic reprogramming of tumor cells that is essential for sustaining their phenotype of fast multiplication by continuously supplying energy and mass. Pyruvate kinase M2 (PKM2) has a vital role in this process, which has given it high interest as a target for anticancer drug development. With potent toxicity to many types of cancer cells, polyphyllin II ( PP2 ), a steroidal saponin isolated from the herbaceous plant Rhizoma paridis , brought to our attention that it might interfere with the PKM2 activity. In this study, we discovered that PP2 was a novel agonist of PKM2. PP2 activated recombinant PKM2 and changed the protein's oligomeric state to activate intracellular PKM2. At the same time, PP2 suppressed its protein kinase function by decreasing the content of nuclear PKM2. The mRNA levels of its downstream genes, such as Glut1 , LDHA , and MYC , were inhibited. In addition, PP2 induced oxidative stress by downregulating the expression and activity of antioxidant proteins such as NQO1, TrxR, and Trx in HT-1080 cells, which in turn led to mitochondrial dysfunction and ultimately induced apoptosis. Moreover, PP2 reduced the proliferation and migration of HT-1080 cells. Thus, targeting the glycolysis pathway offers an unprecedented mode of action for comprehending PP2 's pharmacological impacts and advances PP2 's further development in fibrosarcoma therapy.
Keyphrases
- induced apoptosis
- endoplasmic reticulum stress
- signaling pathway
- oxidative stress
- protein kinase
- cell cycle arrest
- poor prognosis
- stem cells
- binding protein
- pi k akt
- gene expression
- hydrogen peroxide
- tyrosine kinase
- cell death
- small molecule
- nitric oxide
- genome wide
- cell proliferation
- working memory
- living cells
- quantum dots
- amino acid
- sensitive detection
- cancer therapy